ArticleClinical and experimental nephrology2023
eGFR slope as a surrogate endpoint for clinical study in early stage of chronic kidney disease: from The Japan Chronic Kidney Disease Database.
Article in Clinical and experimental nephrology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 2 syntheses or guidelines pooled it, 24 citations in OpenAlex.
- Guidelines for clinical evaluation of chronic kidney disease in early stages : AMED research on regulatory science of pharmaceuticals and medical devices.Clinical and experimental nephrology · 2024Guideline
- Mathematical expansion and clinical application of chronic kidney disease stage as vector field.PloS one · 2024Pooled it
- Efficacy of luseogliflozin for renal function preservation in patients with type 2 diabetes mellitus and impaired renal function: A randomized open-label clinical trial (RESOLUTION study).Journal of diabetes investigation · 2025Trial
- Length of Follow-Up Time Needed for Stable eGFR Slope Estimation in Glomerular Disease.Kidney360 · 2026Article
- Renal tubular calcium phosphate microcrystallopathy and age-related kidney function decline: The Aging Kidney Study.Clinical kidney journal · 2026Article
- Prediction of estimated glomerular filtration rate slope and kidney prognosis of patients with chronic kidney disease.Scientific reports · 2026Article
- Proteinuria reduction as a surrogate endpoint for clinical study of IgA nephropathy in Japanese patients: data from the J-CKD-DB-Ex.Clinical and experimental nephrology · 2026Observational
- Risk factors for persistent decline in eGFR of Japanese patients with diabetes: Analysis using a large-scale diabetes registry J-DREAMS.Journal of diabetes investigation · 2026Article
- Diabetic peripheral neuropathy as measured using a point-of-care sural nerve conduction device is associated with a faster decline in renal function in patients with type 2 diabetes.Journal of diabetes investigation · 2026Observational
- Article
- The Aging Kidney and Exercise Training Study: protocol for a randomized controlled trial within cohorts (TwiCs) study.BMC nephrology · 2025Article
- Chronic kidney disease risk assessment: Findings from backward-looking study using annual health check-up data in Japan.Diabetes, obesity & metabolism · 2025Article
- Article
- Predictive utility of nomogram based on serum glucose-regulated protein 78 and kidney function for long-term kidney graft survival.Scientific reports · 2024Article
- Adding biomarker change information to the kidney failure risk equation improves predictive ability for dialysis dependency in eGFR <30 ml/min/1.73 mClinical kidney journal · 2024Article
- Comparative effects of sodium-glucose cotransporter 2 inhibitors versus dipeptidyl peptidase-4 inhibitors on kidney function decline in Japanese individuals with type 2 diabetes.Clinical and experimental nephrology · 2024Article
- Estimated Glomerular Filtration Rate Slope Predicts Survival and Renal Outcomes in Myeloperoxidase-Antineutrophil Cytoplasmic Antibody-Associated Glomerulonephritis: Development and Validation of a Pathogen-Free Model.Kidney diseases (Basel, Switzerland)Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
Abstract
backgroundIn clinical trials targeting early chronic kidney disease (CKD), eGFR slope has been proposed as a surrogate endpoint for predicting end-stage kidney disease (ESKD). However, it is unclear whether the eGFR slope serves as a surrogate endpoint for predicting long-term prognosis in Japanese early CKD populations.
methodsThe data source was the J-CKD-Database, which contains real-world data on patients with CKD in Japan. eGFR slope was calculated from the eGFR of each period, 1-year (1-year slope), 2-year (2-year slope), and 3-year (3-year slope), for participants with a baseline eGFR ≥ 30 ml/min/1.73 m
resultsThe number of participants and mean observation periods were 7768/877 ± 491 days for 1-year slope, 6778/706 ± 346 days for 2-year slope, and 5219/495 ± 215 days for 3-year slope. As the eGFR slope decreased, a tendency toward a lower risk of ESKD was observed. Compared with the 1-year slope, there was a smaller variation in the slope values for the 2-year or 3-year slope and a greater decrease in the SHR; therefore, a calculation period of 2 or 3 years for the eGFR slope was considered appropriate.
conclusionEven in Japanese patients with early stage CKD, a slower eGFR slope calculated from eGFR values over 2-3 years was associated with a decreased risk of ESKD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.